5-membered heterocyclic P-CAB for stable acid suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing proton pump inhibitors are unstable under acidic conditions and show variability in treatment effects due to metabolic enzyme polymorphism and drug interactions, leading to suboptimal performance in suppressing gastric acid secretion for peptic ulcer and reflux esophagitis.
Innovation Solution
A compound represented by the formula (Ia-34), which is a phenyl or cyclohexyl derivative with specific substituents, acts as a potassium-competitive acid blocker (P-CAB) to reversibly inhibit proton pumps, providing a superior acid secretion suppressive effect without the need for enteric coating and minimizing metabolic variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional proton pump inhibitors are used, then gastric acid secretion is suppressed, but they show instability under acidic conditions requiring enteric coating which delays onset of action
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of proton pump inhibitors to create compounds with improved acid stability. Specifically, the invention introduces a 5-membered heterocyclic ring structure with specific substituents (formula 1) that enhances stability under acidic conditions while maintaining proton pump inhibitory activity, eliminating the need for enteric coating and enabling rapid onset of action.
2Reliability
If conventional proton pump inhibitors are used, then acid secretion is suppressed, but treatment effects show variation due to metabolic enzyme polymorphism and drug interactions
Solution Approach 1:
The patent applies parameter changes by designing a novel chemical structure (formula 1) with specific heterocyclic core and substituent patterns that exhibit reduced susceptibility to metabolic enzyme polymorphism. The compound's structural features lead to more consistent pharmacological responses across different patients, reducing variability in treatment effects while maintaining effective acid suppression.
3Reliability
If enteric coating is applied to protect proton pump inhibitors from acid degradation, then stability is improved, but several hours are required before onset of effect
Solution Approach 1:
The patent resolves this contradiction by changing the chemical parameters of the proton pump inhibitor molecule itself to achieve inherent acid stability without requiring enteric coating. The 5-membered heterocyclic structure with specific substituents (formula 1) maintains structural integrity in acidic environments, allowing the drug to be administered in conventional formulations and act rapidly without delayed-release coatings.
4Reliability
If conventional proton pump inhibitors are used, then proton pump inhibition is achieved, but drug interactions with medicaments such as diazepam occur
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of proton pump inhibitors to create compound (1) with altered metabolic properties. The specific heterocyclic structure and substituent configuration reduce interactions with metabolic enzymes such as CYP3A4, thereby minimizing drug-drug interactions with medications like diazepam while preserving the desired proton pump inhibitory effect.
Data Source
AI summary
Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like. A compound represented by the formula (I) or a salt thereof: wherein ring A is as defined in claim 1; R1 and R2 are each a cyclic group optionally having substituent(s); R3 and R4 are each H or alkyl, or R3 and R4 form, together with the adjacent N, an nitrogen-containing heterocycle; and Y is a spacer.